What Theramir does

Theramir Limited is a Cyprus-based biotechnology company founded in 2017 and headquartered in Limassol, operating from the ASBIS High Tech Cluster. The pre-commercial, R&D-stage company develops microRNA-based therapeutics and a proprietary extracellular vesicle delivery platform for the treatment of aggressive, treatment-resistant, and metastatic cancers. Theramir targets more than 30 malignancy types using a precision oncology approach that aims to customize therapeutic regimens to the molecular pathology of each patient. The company has 1-10 employees and is privately held, with no commercial product revenue to date.

At the core of Theramir's technology is the patented EVmiR platform, which engineers stem cell-derived exosomes and nanoparticles loaded with proprietary panels of biological and synthetic microRNAs to selectively target tumor sites and deliver therapeutic payloads directly into cancer cells. The platform is supported by a published PCT international patent application titled 'MicroRNA-based therapy targeted against LCP-1 positive cancers' (published February 2020). The portfolio is complemented by companion diagnostic tools, including the CompamiR liquid biopsy kit in development for early breast cancer detection, and is being extended into bladder cancer (EXCELL project, 2025) and chronic wound care (MiRACULOUS project, 2023).

Theramir's business model is non-dilutive grant funding combined with a planned licensing and partnership-led commercialization path. The company has secured approximately €1.37 million across grants from the Cyprus Research Promotion Foundation, the Research and Innovation Foundation (IDEK), and the EU Recovery and Resilience Facility, with funding partners including the University of Cyprus, Cyprus University of Technology, European University of Cyprus, and the National Technical University of Athens. Forward revenue is planned through licensing agreements, codevelopment partnerships, and commercial partnerships with biopharmaceutical companies, with no in-house distribution or sales infrastructure currently in place.

Name

Theramir

Legal name

Theramir Limited

Website

https://theramir.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

1–10 employees

Short description

Theramir Limited is a Cyprus-based, pre-commercial biotechnology company developing microRNA-loaded extracellular vesicle (EVmiR) therapeutics and companion diagnostics for precision oncology, with active R&D programs in breast cancer, bladder cancer, and chronic wound care.

Ownership category

akta.pro rank

Product category

Biotechnology / Precision Oncology Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics) (HLAAADAG)

akta.pro secondary industries

Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies) (HLAAANAK), Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)

Keywords

• MicroRNA therapeutics
• Cancer therapeutics
• Extracellular vesicles
• Precision oncology
• Companion diagnostics

Headquarters

HQ city

Limassol

HQ country

Cyprus

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Others

Revenue model

1. Licensing and commercial partnerships: The company plans to generate revenue through licensing agreements and commercial partnerships with biopharmaceutical partners. The company is committed to securing commercial partnerships and licensing agreements with biopharmaceutical partners expected to add substantial value to the company.

Go-to-market motion1 record

Marketing channels4 records

Core offering

Theramir develops a proprietary microRNA-based cancer therapeutics platform (EVmiR) that uses extracellular vesicles/exosomes to selectively deliver therapeutic miRNA payloads into cancer cells, targeting multiple cancer pathways and halting tumor progression and metastasis. The offering is complemented by companion diagnostic tools, including liquid biopsy-based assays (e.g., the CompamiR Diagnostic Kit), for minimally invasive cancer detection and treatment monitoring across more than 30 cancer types.

Product overview

Theramir offers a unified product portfolio centered on its patented EVmiR platform technology for precision oncology. The core offering consists of miRNA-loaded extracellular vesicles (EVmiR) combined with a proprietary panel of microRNA-based therapeutics and an exosome delivery platform. These are complemented by companion diagnostic tools including the CompamiR diagnostic kit for liquid biopsy-based breast cancer detection. The company is expanding applications to bladder cancer through the EXCELL project while also pursuing wound healing through the MiRACULOUS project.

Differentiator

Problem solved

Functional benefit

Brands

• EVmiR: Patented platform technology of miRNA-loaded extracellular vesicles (EVs) that selectively target tumors and disrupt the metastatic process. The technology delivers microRNAs directly into tumors where they target oncogenic proteins that fuel cancer cell proliferation.
• EVmiR Platform

Products and services

• MicroRNA-based Cancer Therapeutics Therapeutic candidates based on microRNAs that target and disrupt multiple cancer pathways simultaneously, intended for biopharmaceutical licensing and development for the treatment of more than 30 cancer types including aggressive and metastatic disease.
• Exosome Delivery Platform Targeted delivery platform using stem cell-derived exosomes and engineered nanoparticles that selectively delivers therapeutic payloads (including miRNAs) directly to tumor sites, intended for biopharmaceutical out-licensing.
• EVmiR Platform Theramir's proprietary integrated platform combining microRNA therapeutics with extracellular vesicle delivery to selectively target tumors and halt cancer progression and metastasis; serves as the foundation for the company's therapeutic pipeline and licensing opportunities.
• Companion Diagnostic Tools Diagnostic assays designed to identify candidate patients for Theramir's miRNA therapeutics and to enable real-time monitoring of treatment response, supporting a precision oncology companion-diagnostic pairing.
• CompamiR Diagnostic Kit Liquid biopsy-based diagnostic kit for minimally invasive cancer detection and patient monitoring, developed as part of the CompamiR project.

Quantifiable outcome

• Successfully disrupted metastatic process in breast cancer models with EVmiR therapeutic platform
• +1 more outcomes

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature3 records

Partnerships

Nine partnerships are on record, tiered core and minor.

• Promed BiosciencecoreStrategic or Co-development Partner · 1 January 2023MiRACULOUS Project collaborator specializing in high-purity medical-grade atelocollagen for regenerative medicine. Partnered with Theramir to develop and characterize specialized atelocollagen biomaterials with key characteristics for wound healing product design.
• RSL Revolutionary LabscoreStrategic or Co-development Partner · 1 January 2023MiRACULOUS Project collaborator providing advanced formulations of natural bioactive extracts tailored for wound healing applications. Contributes to final product development and pilot production.
• Vet Ex Machina LtdcoreStrategic or Co-development Partner · 1 January 2023MiRACULOUS Project collaborator conducting advanced preclinical and veterinary clinical trials including in vivo and ex vivo testing. Leverages state-of-the-art facilities and expertise in tissue engineering, medical devices, and cell-based therapies.
• Hellenic Cooperative Oncology Group (HeCOG)minorStrategic or Co-development Partner · 1 January 2019Provides existing biobanks from Greece for the CompamiR project, supporting early breast cancer diagnosis research using plasma samples from early breast cancer patients.
• University of CypruscoreStrategic or Co-development Partner · 1 January 2018Part of consortium with Cyprus University of Technology, European University of Cyprus, and Theramir Ltd awarded infrastructure grant from Research Promotion Foundation to establish joint Center for Preclinical Evaluation and Optimization of Cancer Nanomedicines.
• Cyprus University of TechnologycoreStrategic or Co-development Partner · 1 January 2018Consortium partner in Cancer Nanomedicines center grant and MICROCURE project collaboration. Partner in 1st Cancer Research Workshop organized by Cancer Research Centre.
• European University of CyprusminorStrategic or Co-development Partner · 1 January 2018Consortium partner in Cancer Nanomedicines center infrastructure grant from Research Promotion Foundation.
• German Oncology CentercoreStrategic or Co-development Partner · 1 January 2018Clinical research partner collaborating on cancer research initiatives including Cancer Research Centre, a bench-to-bedside hub for cancer diagnosis, treatment, care and prevention.
• National Technical University of Athens (NTUA)minorStrategic or Co-development Partner · 1 January 2018Academic partner collaborating with Theramir and Cyprus University of Technology on MICROCURE project for metastasis-specific miRNA biomarker investigation and therapeutic agent development.

Scale indicators7 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Arcturus Therapeutics: Clinical-stage RNA therapeutics company with platforms spanning mRNA, siRNA, and lipid nanoparticle delivery. Comparable to Theramir in developing RNA-based oncology and rare disease therapeutics with proprietary delivery technology, but at a much later clinical stage.
• Alnylam Pharmaceuticals: Established global leader in RNA interference therapeutics (siRNA). Operates in the broader RNA-therapeutics space that encompasses Theramir's miRNA approach, but at vastly greater scale, with multiple approved drugs and a commercial infrastructure Theramir would need a partner to access.
• Translate Bio (Sanofi): mRNA therapeutics platform acquired by Sanofi, working on vaccines and protein-replacement applications. Adjacent peer given Theramir's RNA-therapeutic ambitions, though Translate Bio's mRNA focus differs from miRNA/EV delivery.

Direct peers

• Aegle Therapeutics: Clinical-stage company developing extracellular vesicle (EV) therapies for dermatology and rare diseases. Shares Theramir's core approach of using stem-cell-derived vesicles as therapeutic delivery vehicles, though Aegle focuses on dermatology indications.
• MiNA Therapeutics: UK-based clinical-stage company pioneering RNA activation (RNAa) therapeutics in oncology. Closely comparable to Theramir's RNA-based oncology focus, though MiNA's mechanism (saRNA) differs from miRNA-loaded EVs.
• Capricor Therapeutics: Clinical-stage biotech advancing extracellular vesicle-based therapies (CAP-1002, exosome candidates). Comparable to Theramir's use of cell-derived vesicles as a delivery modality, with Capricor further along clinically and publicly traded.
• Evox Therapeutics: UK-based biotech developing exosome-based therapeutics for rare diseases and oncology. Directly comparable to Theramir's EVmiR platform in leveraging engineered extracellular vesicles for targeted therapeutic delivery, although Evox has deeper funding and a broader pipeline.

Emerging players

• ExoCoBio: South Korea-based exosome therapeutics and cosmetic company developing stem-cell-derived EV products. Shares Theramir's exosome-delivery technology base, with a current focus on cosmetics/regenerative medicine rather than oncology.
• Bio-Path Holdings: Clinical-stage oncology company developing DNA/RNA-based therapeutics (lipid-conjugated DNA platform). Comparable to Theramir in targeting oncology with nucleic-acid therapeutics, though using a different delivery modality and at later clinical stage.
• Carmine Therapeutics: Singapore/US biotech developing red-blood-cell-derived extracellular vesicle therapeutics for gene therapy and oncology. Closely comparable to Theramir's engineered EV delivery approach, though targeting a different vesicle source.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Theramir